Sienna Biopharmaceuticals   Report issue

For profit Phase 2
Founded: Westlake Village CA United States (2010)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2017
NCT03322137
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sienna Biopharmaceuticals

Active Ingredients

Drugs in Phase 2 Trials (3)

Key: Sienna Biopharmaceuticals (2) Acquired (1)

calcipotriene (dovonex) (1 trial)

ct327 (7 trials)

sna-120 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pruritus (Phase 2)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 3